# Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Source: https://onco.cc/trials/nct02477696/  
OnCo record `nct02477696` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Acalabrutinib and Ibrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.

## Summary

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) is a phase 3 interventional study registered as NCT02477696 by Acerta Pharma BV, with 533 participants enrolled, started 2015-07-28 and due to reach its primary completion in 2020-09-15. Interventions recorded: Acalabrutinib and Ibrutinib. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02477696
- Phase: 3
- Setting: A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
- Sponsor: Acerta Pharma BV
- Enrolled: 533

## Sources

- ClinicalTrials.gov NCT02477696: https://clinicaltrials.gov/study/NCT02477696

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Ibrutinib](https://onco.cc/drugs/ibrutinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct02477696.json